2024 Costa Rica Breast Cancer Diagnostics Market--CEA, CA 15-3, CA 27.29,CA 125, Estrogen Receptor, HER2, Polypeptide-Specific Antigen, Progesterone Receptor--Country Database and Analysis--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation, Growth Opportunities

January 2024 | | ID: 2F0E206341C1EN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com is available by market segment, section, individual marker, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding breast cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for major breast cancer markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current assays and instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The breast cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide breast cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Supplier Shares, Sales and Volume Forecasts

• Sales and market shares of major suppliers
• Five-year test volume and sales forecasts by assays

Instrumentation Review

• Analysis of major analyzers used for breast cancer testing

Technology Assessment

• Assessment of latest technologies and their potential applications for breast cancer diagnostic testing
• Review of competing/complementing technologies
• Companies, universities and research centers developing new breast cancer diagnostic tests and detection technologies

Competitive Strategies

• Strategic assessments of major suppliers and start-up firms developing innovative breast cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
• The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujirebio, Fujifilm Wako, Grifols, Hologic, Leica Biosystems, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher, and others.

Contents

I. Introduction
II. Worldwide Market Overview
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology

1. BREAST CANCER


2. LUNG CANCER


3. COLON AND RECTUM CANCER


4. PROSTATE CANCER


5. STOMACH CANCER


6. LEUKEMIA


7. LYMPHOMA


8. ORAL CANCER


9. SKIN CANCER


10. UTERINE CANCER


11. OVARIAN CANCER


12. BLADDER CANCER

B. Major Current and Emerging Cancer Diagnostic Tests

1. INTRODUCTION


2. TUMOR MARKER CLASSIFICATION


3. ACTH


4. ALPHA-FETOPROTEIN (AFP)


5. BETA-2 MICROGLOBULIN


6. CA 15-3/27.29


7. CA 19-9


8. CA-125


9. CALCITONIN


10. CARCINOEMBRIONIC ANTIGEN (CEA)


11. ESTROGEN AND PROGESTERONE RECEPTORS


12. FERRITIN


13. GASTRIN


14. HUMAN CHORIONIC GONADOTROPIN (HCG)


15. INSULIN


16. NSE


17. OCCULT BLOOD


18. PAP SMEAR/HPV


19. PROSTATIC ACID PHOSPHATASE (PAP)


20. PROSTATE-SPECIFIC ANTIGEN (PSA)


21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)


22. T AND B LYMPHOCYTES


23. TDT


24. THYROGLOBULIN


25. TISSUE POLYPEPTIDE ANTIGEN (TPA)


26. BIOCHEMICAL TUMOR MARKERS


27. ONCOGENES

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others

28. POLYPEPTIDE GROWTH FACTORS

- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES


30. COLONY STIMULATING FACTORS


31. LYMPHOKINES

- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS


33. EMERGING TUMOR MARKERS

- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA
- CA 72-4/TAG-72
- CA
- CA-242
- CA-549
- CAM
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies

1. MONOCLONAL AND POLYCLONAL ANTIBODIES


2. IMMUNOASSAYS


3. MOLECULAR DIAGNOSTICS


4. CHROMOSOME ANALYSIS

a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes

5. ARTIFICIAL INTELLIGENCE


6. FLOW CYTOMETRY


7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)


8. BIOSENSORS


9. COMPETING/COMPLEMENTING TECHNOLOGIES

E. Personal Testing